Drug Profile
Research programme: GHRH antagonists - AEterna Zentaris
Alternative Names: JMR-132Latest Information Update: 27 Apr 2010
Price :
$50
*
At a glance
- Originator Tulane University
- Developer AEterna Zentaris Inc
- Class
- Mechanism of Action Growth hormone-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer